

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. *N Engl J Med* 2006;354:809-20.

Table S1. Events in the study

	<u>All patients in the study</u>		<u>Patients with <i>erbB2</i> amplification</u>	
	Docetaxel/ FEC	Vinorelbine/ FEC	Trastuzumab	No trastuzumab
Number of patients	502	507*	115*	116
Patient alive, event-free	460	436	103	89
Patients with any event†	42	71	12	27
Distant recurrence	33	58	8	26
Locoregional recurrence	9	17	2	6
Contralateral breast cancer	6	10	3	1
Death with no evidence of breast cancer	2	1	1	1
Any death	20	30	6	14
Second primary cancer	1	5	0	2

*One patient with overt distant metastasis at the time of randomization was excluded from efficacy analyses.

†Patients with any recurrence, or death without prior recurrence.